Trial Profile
An Exploratory, Randomized, Controlled Study of Tenofovir Plus Telbivudine Versus Monotherapy With Either Drug Alone in HBeAg Negative Chronic Hepatitis B Patients
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 18 Jun 2015
Price :
$35
*
At a glance
- Drugs Telbivudine (Primary) ; Tenofovir (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- 15 Jun 2015 Status changed from recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
- 28 Jun 2011 Actual initiation date (Jun 2011) added as reported by ClinicalTrials.gov.
- 28 Jun 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.